Saturday, June 10, 2023
Mitochondrial Health

March 30, 2022 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee

The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic lateral sclerosis (ALS).


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *